Immunotherapy: incorporation in the evolving paradigm of renal cancer management and future prospects
Metrics: PDF 1234 views | HTML 1618 views | ?
Kenneth G. Liu1, Sorab Gupta2 and Sanjay Goel1
1 Department of Medical Oncology, Montefiore Medical Center, Bronx, NY, USA
2 Department of Internal Medicine, St. Barnabas Hospital, Bronx, NY, USA
Sanjay Goel, email:
Keywords: renal cell carcinoma; immunotherapy; checkpoint Inhibition; cytokines; vaccines
Received: August 20, 2016 Accepted: December 13, 2016 Published: December 30, 2016
Significant progress has been made in the management of renal cell carcinoma (RCC) during the last few decades. In early stage, localized disease, surgical resection remains the modality of choice, with no therapeutic interventions as options for post-operative therapy other than simple observation and clinical surveillance. However, treatment options in the advanced or metastatic setting are increasing at a dizzying pace, initially with cytokine therapy, then with the increased availability of targeted therapy including novel small-molecule inhibitors of receptor tyrosine kinases and monoclonal antibodies targeting novel proteins, establishing them as the current standard of care. Even more recently, immunotherapy has seen tremendous development in the form of immune checkpoint inhibition and vaccines. Overall, these interventions have gradually changed the landscape of cancer management in general, and metastatic renal cell carcinoma (mRCC) in particular. This is exemplified by the recent United States Food and Drug Administration (USFDA) approval of nivolumab for patients with mRCC after failure of TKI therapy. In this review, we present a brief overview of the current management of mRCC, primarily the clear cell subtype (ccRCC), and discuss the major clinical trials and data on the immunotherapy in advanced or mRCC.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.